Semaglutide Research: What the Main Studies Found
The largest heart study gives the clearest result
The strongest study counted deaths tied to the heart, along with strokes and heart attacks. Those problems occurred 20% less often among people taking Semaglutide [3]. Everyone had both heart disease and excess weight, so ask whether that group resembles you.
Semaglutide copies GLP-1, a gut hormone that guides hunger and blood sugar [12]. Other studies looked at weight, kidney health, and liver disease. You’ll see what each study showed, what it only suggested, and what remains unknown.
What is Semaglutide: a medicine that copies a gut hormone
Semaglutide is a 31-amino-acid protein; amino acids are small units used to build proteins [12]. It copies GLP-1, a hormone that your gut sends out after a meal. About 94% of its protein parts match the natural hormone, letting the medicine work in some of the same places. As blood sugar goes up, the hormone helps your pancreas move insulin into the blood [12].
GLP-1 helps your brain register a full meal and also slows your stomach. Semaglutide can do those jobs for much longer. At a clinic, you may hear it called a GLP-1 medicine [12], which means the medicine copies this gut hormone.
The semaglutide peptide, a small protein, was made to last longer
The semaglutide peptide, which is a small protein, was changed so it wouldn’t fade within minutes [12]. One protein part is marked as number 8 in the lab. That change resists DPP-4, a body substance that would break down GLP-1, the natural gut hormone, very fast [12].
A fat-like part helps the medicine attach to one of the main proteins in your blood [12]. Your kidneys then remove it slowly. Semaglutide can remain for about five weeks [12], even after you no longer feel an effect.
Large studies found fewer serious heart problems
The largest study included 17,604 adults who had no diabetes but were living with heart disease. Each had a body mass index of 27 or more, meaning weight was high for height. With Semaglutide 2.4 mg, heart attack, stroke, or death tied to the heart occurred 20% less often [3]. The first 95% range backed that plain result, and another test made chance a poor explanation. A 2024 review saw the benefit at different starting weights [13].
An earlier diabetes heart study called SUSTAIN-6 included 3,297 people with type 2 diabetes and a serious risk of heart trouble. At 0.5 or 1.0 mg, Semaglutide cut the same three problems by 26% [2]. The second 95% range also favored the medicine.
A tablet study called PIONEER 6 did not prove that the tablet prevented more heart trouble than placebo. It did show that the tablet was at least as safe for the heart as placebo in type 2 diabetes [8]. In a separate heart-failure group, another study found symptom relief and fewer daily limits with Semaglutide 2.4 mg [9]. The semaglutide heart failure page explains who took part.
Semaglutide weight loss was large but didn’t last by itself
STEP 1 was a weight study of 1,961 adults without diabetes who carried excess weight. At 68 weeks, average weight fell 14.9% with Semaglutide and 2.4% with placebo [1]. STEP 1 and STEP 4 also recorded better blood sugar, lower blood pressure, and smaller waists [10].
The change held while people took the medicine, but the studies don’t show a cure. The effects page explains how much weight came back after treatment ended.
A kidney study found fewer major kidney problems
The kidney study followed 3,533 people whose type 2 diabetes came with lasting damage to the kidneys. With Semaglutide 1.0 mg, major kidney problems occurred 24% less often [7]. Researchers counted kidney failure, kidneys working 50% less, or death caused by kidney or heart trouble. Its 95% range supported fewer kidney problems.
Another diabetes study compared Semaglutide 2.0 mg with 1.0 mg. The higher amount produced a larger drop on the blood test for long-term sugar levels [20]. One review covers these uses and amounts together [12].
Semaglutide vs tirzepatide: more weight came off with tirzepatide
The direct study was fairly small and lasted 72 weeks. It included 751 adults with extra weight. In the study called SURMOUNT-5, average weight fell 20.2% with tirzepatide and 13.7% with Semaglutide [21]. Its check found that chance was a poor fit for the gap.
A 2025 paper estimated how heart risk might differ across 10-year spans [22]. It did not follow people for those years. The weight gap was about 6.5 percentage points. Semaglutide, meanwhile, has a large study that counted heart problems [3].
Semaglutide side effects most often involve the stomach
The safety review had too few cases to settle rare harms, including possible cancer of the pancreas or thyroid [5]. The common Semaglutide side effects were nausea, vomiting, constipation, and diarrhea.
Gallstones and other trouble in the gallbladder also happened more often. In SUSTAIN-6, the diabetes heart study, eye trouble rose for some people whose blood sugar dropped fast [2]. The effects page separates study findings from personal accounts, helping you judge how well each claim is backed.
Compounded Semaglutide, prepared at a pharmacy, wasn’t tested here
A pharmacy, rather than the usual medicine maker, prepares compounded Semaglutide. This option was allowed during a national shortage. Reports described hospital stays, mistakes in the amount, and products with an unchecked main ingredient [5]. The shortage ended in 2025, so officials narrowed the temporary permission for pharmacies [12].
The large studies used medicine made by the usual company, so they can’t tell you whether a pharmacy-made product acts the same. Remember that gap when comparing its claims with study results.
Some serious questions still have no firm answer
The thyroid warning came from rats and mice given high amounts [6][5]. Studies in people haven’t found a clear rise in that rare thyroid cancer, and pancreas cancer reports are too few for a firm answer [5].
People have also reported mood and behavior changes, but studies haven’t shown that Semaglutide caused them [5]. One point is clearer: weight returned in large measure after treatment ended [19]. For you, an open risk deserves a place beside a proven benefit.